Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine

Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine

Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of mortality in case of contamination (more than 20% of mortality in this population). However, vaccine efficiency is known to be decreased in haemodialysis patients. This lead critical the rapid description of immunogenicity of anti SARS-Cov2 vaccine in haemodialysis patients.

The aim of this study is to describe the immunogenicity of the BTN162b2 SARS-Cov2 vaccine in haemodialysis patients.

Inclusion Criteria:

• Medical prescription of BTN162b2 mRNA Cov-19 vaccine
• Treatment by chronic (>1 month) haemodialysis

Exclusion Criteria:

• Non-recommended vaccination scheme
• Refusal to consent